From Name:
From Email:
To Name:
To Email:

Optional Message:


Seeking edge in oncology, Bristol-Myers bets big on blood cancer, cell therapies

from BioPharma Dive

Already a leader in therapies for solid tumors, Bristol-Myers Squibb's $74 billion bid for Celgene and its blood cancer business could help the big pharma in its rivalry with oncology powerhouse Merck & Co. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063